We are live on ! Find out more
SGH

Sivik Global Healthcare Portfolio holdings

AUM $132M
1-Year Est. Return 24.1%
This Fund
S&P 500
This Quarter Est. Return
+7.55%
1 Year Est. Return
+24.1%
3 Year Est. Return
+53.78%
5 Year Est. Return
+97.1%
10 Year Est. Return
+690.63%
AUM
$201M
AUM Growth
-$24.7M
Cap. Flow
-$35.3M
Cap. Flow %
-17.56%
Top 10 Hldgs %
29.72%
Holding
72
New
14
Increased
15
Reduced
25
Closed
16

Top Buys

Rank Stock Value
1
SYK icon
Stryker
SYK
+$5.59M
2
MRK icon
Merck
MRK
+$5.02M
3
JNJ icon
Johnson & Johnson
JNJ
+$4.55M
4
GSK icon
GSK
GSK
+$4.21M
5
ESRX
Express Scripts Holding Company
ESRX
+$4.04M

Top Sells

Rank Stock Value
1
MCK icon
McKesson
MCK
+$8.02M
2
UNH icon
UnitedHealth
UNH
+$8M
3
AET
Aetna Inc
AET
+$7.46M
4
WBA
Walgreens Boots Alliance
WBA
+$5.9M
5
ABT icon
Abbott
ABT
+$5.23M

Sector Composition

Rank Sector Weight
1 Healthcare 89.51%
2 Energy 1.94%
3 Financials 1.82%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZBH icon
1
Zimmer Biomet
ZBH
$18.8B
$7.22M 3.59%
61,800
+10,300
+20% +$1.17M
BSX icon
2
Boston Scientific
BSX
$68.4B
$7.01M 3.49%
300,000
– –
CNC icon
3
Centene
CNC
$30.5B
$6.52M 3.24%
182,600
-17,400
-9% -$546K
UHS icon
4
Universal Health Services
UHS
$10.2B
$6.04M 3%
45,000
-30,000
-40% -$3.96M
SYK icon
5
Stryker
SYK
$135B
$5.99M 2.98%
+50,000
New +$5.59M
VRTX icon
6
Vertex Pharmaceuticals
VRTX
$123B
$5.59M 2.78%
65,000
+45,000
+225% +$3.89M
HCA icon
7
HCA Healthcare
HCA
$90.6B
$5.46M 2.71%
70,900
-54,100
-43% -$4.27M
CELG
8
DELISTED
Celgene Corp
CELG
$5.42M 2.7%
55,000
+15,000
+38% +$1.55M
AMGN icon
9
Amgen
AMGN
$209B
$5.33M 2.65%
35,000
+20,000
+133% +$3.11M
MDT icon
10
Medtronic
MDT
$112B
$5.21M 2.59%
60,000
+15,000
+33% +$1.21M
MRK icon
11
Merck
MRK
$322B
$5.18M 2.58%
+94,320
New +$5.02M
JNJ icon
12
Johnson & Johnson
JNJ
$640B
$4.85M 2.41%
+40,000
New +$4.55M
THC icon
13
Tenet Healthcare
THC
$22.2B
$4.84M 2.4%
175,000
+15,000
+9% +$443K
BIIB icon
14
Biogen
BIIB
$30.9B
$4.84M 2.4%
20,000
+5,000
+33% +$1.32M
SHPG
15
DELISTED
Shire pic
SHPG
$4.6M 2.29%
25,000
+5,000
+25% +$903K
A icon
16
Agilent Technologies
A
$39.6B
$4.44M 2.21%
100,076
+5,076
+5% +$219K
TMO icon
17
Thermo Fisher Scientific
TMO
$214B
$4.43M 2.2%
30,000
– –
GSK icon
18
GSK
GSK
$107B
$4.33M 2.15%
+80,000
New +$4.21M
ESRX
19
DELISTED
Express Scripts Holding Company
ESRX
$4.17M 2.07%
+55,000
New +$4.04M
BMY icon
20
Bristol-Myers Squibb
BMY
$129B
$4.04M 2.01%
55,000
-25,000
-31% -$1.77M
LLY icon
21
Eli Lilly
LLY
$1.08T
$3.94M 1.96%
+50,000
New +$3.76M
LH icon
22
Labcorp
LH
$25.2B
$3.91M 1.94%
+34,920
New +$3.76M
LHCG
23
DELISTED
LHC Group LLC
LHCG
$3.9M 1.94%
90,000
-20,000
-18% -$815K
AET
24
DELISTED
Aetna Inc
AET
$3.66M 1.82%
30,000
-65,000
-68% -$7.46M
DGX icon
25
Quest Diagnostics
DGX
$26B
$3.66M 1.82%
+45,000
New +$3.43M
1
2 3

Similar funds

RSF
Rik Saylor Financial Fairfield, Ohio $132M AUM 16.04% 1-Year Est. Return
VF
Visa Foundation San Francisco, California $132M AUM 14.62% 1-Year Est. Return
AFP
ATX Financial Planning Austin, Texas $132M AUM
GCM
Graver Capital Management Columbus, Ohio $132M AUM 16.79% 1-Year Est. Return
TCPW
Twin City Private Wealth Winston-Salem, North Carolina $132M AUM 11.31% 1-Year Est. Return
GCM
Gunpowder Capital Management Towson, Maryland $132M AUM
FF
Fairway Financial Casselberry, Florida $132M AUM 13.23% 1-Year Est. Return
PF
PlanVest Financial Gaithersburg, Maryland $131M AUM

Sivik Global Healthcare's Q2 2016 Portfolio in Review

As of Q2 2016, Sivik Global Healthcare held 72 positions worth $201M, down 11% from $226M the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Sivik Global Healthcare withdrew a net $35.3M in Q2 2016, closing 16 positions and reducing 25 holdings. Its most notable exit was McKesson, an estimated $8.02M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 87% a quarter earlier, followed by Energy and Financials.

Against the trend, Sivik Global Healthcare opened a new position in Stryker worth $5.99M.

  • Sivik Global Healthcare's largest Q2 2016 buy was Stryker: 50,000 shares worth $5.99M.
  • Sivik Global Healthcare added most to Vertex Pharmaceuticals in Q2 2016, an estimated $3.89M increase.
  • Sivik Global Healthcare's biggest Q2 2016 reduction was UnitedHealth, cutting an estimated $8M.
  • Sivik Global Healthcare fully exited McKesson in Q2 2016, selling an estimated $8.02M.
  • Sivik Global Healthcare's ten largest holdings make up 30% of its $201M portfolio in Q2 2016.
  • Sivik Global Healthcare opened 14 new positions and closed 16 in Q2 2016.
  • Sivik Global Healthcare's portfolio value fell 11% quarter-over-quarter to $201M.

Based on Sivik Global Healthcare's 13F filing for Q2 2016, filed 5 Aug 2016.